02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
18:29 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Sun's IL-23 psoriasis mab approved by FDA

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit alpha...
18:41 , Mar 21, 2018 |  BC Extra  |  Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit alpha...
18:14 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia (CLL) Patient sample, cell culture and mouse studies suggest inhibiting IL23P19-IL-23 receptor signaling could help treat CLL. In peripheral blood mononuclear cells (PBMCs) from patients, high levels of IL-23 receptor were...
00:20 , Dec 22, 2017 |  BC Innovations  |  Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
19:21 , Sep 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro and mouse studies identified a hedgehog pathway inhibitor that could help treat medulloblastoma. Optimization and testing in mouse fibroblast cell-based assays of a previously identified dihydrobenzooxazocin analog yielded a compound that...
23:42 , Sep 14, 2017 |  BC Extra  |  Company News

Management tracks: SymCel, Taro, Akcea

SymCel Sverige AB (Spanga, Sweden) named Jesper Ericsson CEO. He was director of marketing and sales at BioLamina AB (Stockholm, Sweden). SymCel offers a cell-based assay for real-time monitoring of cell metabolism. Prescription and OTC pharma...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
21:00 , Jun 1, 2017 |  BC Week In Review  |  Clinical News

FDA reviewing Sun's psoriasis candidate tildrakizumab

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA accepted for review a BLA for tildrakizumab (MK-3222) to treat moderate to severe plaque psoriasis. The company declined to disclose the PDUFA date. In March, EMA validated an...